scholarly journals The Practical Application of Emerging Technologies Influencing the Diagnosis and Care of Patients With Primary Brain Tumors

2020 ◽  
pp. e35-e46 ◽  
Author(s):  
Leland S. Hu ◽  
Daniel J. Brat ◽  
Orin Bloch ◽  
Shakti Ramkissoon ◽  
Glenn J. Lesser
Keyword(s):  
Brain Tumors ◽  
Surgical Navigation ◽  
Tumor Biology ◽  
Primary Brain Tumors ◽  
Tumor Treating Fields ◽  
Histopathologic Diagnosis ◽  
Therapeutic Decision Making ◽  
Next Generation Sequencing Ngs ◽  
Ngs Data

Over the past decade, a variety of new and innovative technologies has led to important advances in the diagnosis and management of patients with primary malignant brain tumors. New approaches to surgical navigation and tumor localization, advanced imaging to define tumor biology and treatment response, and the widespread adoption of a molecularly defined integrated diagnostic paradigm that complements traditional histopathologic diagnosis continue to impact the day-to-day care of these patients. In the neuro-oncology clinic, discussions with patients about the role of tumor treating fields (TTFields) and the incorporation of next-generation sequencing (NGS) data into therapeutic decision-making are now a standard practice. This article summarizes newer applications of technology influencing the pathologic, neuroimaging, neurosurgical, and medical management of patients with malignant primary brain tumors.

scholarly journals The role of CXCR3/LRP1 cross-talk in the invasion of primary brain tumors

2017 ◽  
Vol 8 (1) ◽  
Author(s):  
Kevin Boyé ◽  
Nadège Pujol ◽  
Isabel D Alves ◽  
Ya-Ping Chen ◽  
Thomas Daubon ◽  
...  
Keyword(s):  
Brain Tumors ◽  
Cross Talk ◽  
Primary Brain Tumors

scholarly journals Role of SOD2 Ala16Val polymorphism in primary brain tumors

2019 ◽  
Author(s):  
Ayca Taş ◽  
Yavuz Silig ◽  
Hatice Pinarbaşi ◽  
Mustafa G�relik
Keyword(s):  
Brain Tumors ◽  
Primary Brain Tumors

scholarly journals Role of magnetic resonance spectroscopy in grading of primary brain tumors

2016 ◽  
Vol 47 (2) ◽  
pp. 577-584 ◽  
Author(s):  
Radwa Kamel Abdel Naser ◽  
Afaf Abdel Kader Hassan ◽  
Amr Mohamed Shabana ◽  
Nagham Nabil Omar
Keyword(s):  
Magnetic Resonance ◽  
Magnetic Resonance Spectroscopy ◽  
Brain Tumors ◽  
Resonance Spectroscopy ◽  
Primary Brain Tumors

scholarly journals CSI NGS Portal: An Online Platform for Automated NGS Data Analysis and Sharing

2020 ◽  
Vol 21 (11) ◽  
pp. 3828
Author(s):  
Omer An ◽  
Kar-Tong Tan ◽  
Ying Li ◽  
Jia Li ◽  
Chan-Shuo Wu ◽  
...  
Keyword(s):  
Data Analysis ◽  
Final Report ◽  
Online Platform ◽  
Fastq Format ◽  
Health And Disease ◽  
Ngs Data Analysis ◽  
Next Generation Sequencing Ngs ◽  
User Friendly ◽  
Ngs Data

Next-generation sequencing (NGS) has been a widely-used technology in biomedical research for understanding the role of molecular genetics of cells in health and disease. A variety of computational tools have been developed to analyse the vastly growing NGS data, which often require bioinformatics skills, tedious work and a significant amount of time. To facilitate data processing steps minding the gap between biologists and bioinformaticians, we developed CSI NGS Portal, an online platform which gathers established bioinformatics pipelines to provide fully automated NGS data analysis and sharing in a user-friendly website. The portal currently provides 16 standard pipelines for analysing data from DNA, RNA, smallRNA, ChIP, RIP, 4C, SHAPE, circRNA, eCLIP, Bisulfite and scRNA sequencing, and is flexible to expand with new pipelines. The users can upload raw data in FASTQ format and submit jobs in a few clicks, and the results will be self-accessible via the portal to view/download/share in real-time. The output can be readily used as the final report or as input for other tools depending on the pipeline. Overall, CSI NGS Portal helps researchers rapidly analyse their NGS data and share results with colleagues without the aid of a bioinformatician. The portal is freely available at: https://csibioinfo.nus.edu.sg/csingsportal.

PO-0638 ROLE OF 11C-MET PET FOR RADIOTHERAPY PLANNING OF PRIMARY BRAIN TUMORS

2012 ◽  
Vol 103 ◽  
pp. S250
Author(s):  
E. Lopci ◽  
E. Clerici ◽  
M. Catalano ◽  
M. Rodari ◽  
P. Navarria ◽  
...  
Keyword(s):  
Brain Tumors ◽  
Radiotherapy Planning ◽  
Primary Brain Tumors ◽  
Met Pet

scholarly journals Pivotal therapeutic trials for infiltrating gliomas and how they affect clinical practice

2016 ◽  
Vol 4 (4) ◽  
pp. 209-219 ◽  
Author(s):  
Rimas V Lukas ◽  
Maciej M Mrugala
Keyword(s):  
Brain Tumors ◽  
Clinical Decision Making ◽  
Clinical Decision ◽  
Low Grade ◽  
Nccn Guidelines ◽  
Primary Brain Tumors ◽  
Tumor Treating Fields ◽  
Therapeutic Trials ◽  
Therapeutic Landscape ◽  
The Us

Abstract The therapeutic landscape of the management of low- and high-grade infiltrating gliomas continues to evolve. Daily clinical decision making in neuro-oncology clinics across the US is frequently challenging, especially for anaplastic and low grade primary brain tumors. The focus of this review is centered on treatments which are approved by the FDA and/or featured in the NCCN Guidelines. Systemic therapy trials using a variety of agents such as temozolomide, bevacizumab, and procarbazine, lomustine, vincristine (PCV), and lastly trials of local therapies including surgical trials using carmustine impregnated wafers as well as trials investigating the administration of tumor treating fields are evaluated. Pivotal trials on the treatment of the primary brain tumors are discussed in detail along with associated correlative studies.

scholarly journals Role of RGMc as a Neogenin Ligand in Follicular Development in the Ovary

Biomedicines ◽  
2021 ◽  
Vol 9 (3) ◽  
pp. 280
Author(s):  
Yu Jin Kim ◽  
YoungJoon Park ◽  
Yeo Reum Park ◽  
Young Sang Kim ◽  
Hye Ran Lee ◽  
...  
Keyword(s):  
Signaling Pathway ◽  
Follicular Development ◽  
Ovarian Response ◽  
Cumulus Cells ◽  
Prostaglandin D2 ◽  
Repulsive Guidance Molecule ◽  
Next Generation Sequencing Ngs ◽  
Ngs Data ◽  
Guidance Molecule

There is currently no cure for infertility in women with a poor ovarian response (POR). Neogenin is reported to be abundantly expressed in the ovary; however, its role in mammalian follicular development is unclear and its ligand and signaling pathway remain uncertain. We systematically investigated the role of neogenin and the ligand repulsive guidance molecule c (RGMc) during follicular development. We treated hyperstimulated mouse ovaries with RGMc and analyzed follicular development. Furthermore, we investigated clusters of up/downregulated genes in RGMc-treated ovaries using whole-transcriptome next-generation sequencing (NGS). In addition, we investigated whether expression of up/downregulated factors identified by NGS was also altered in cumulus cells (CCs) of patients with a POR. The number of oocytes was 40% higher in RGMc-treated ovaries than in control ovaries. NGS data indicated that prostaglandin D2 (PGD2) was involved in the RGMc signaling pathway during follicular development. RGMc treatment significantly elevated the PGD2 level in culture medium of CCs obtained from patients with a POR. Our results demonstrate that RGMc as neogenin ligand promotes follicular development in ovaries via the PGD2 signaling pathway. Therefore, it may be possible to use RGMc for ovarian stimulation in patients with a POR.

scholarly journals The Role of MicroRNAs in Therapeutic Resistance of Malignant Primary Brain Tumors

2021 ◽  
Vol 9 ◽  
Author(s):  
Ilgiz Gareev ◽  
Ozal Beylerli ◽  
Yanchao Liang ◽  
Huang Xiang ◽  
Chunyang Liu ◽  
...  
Keyword(s):  
Brain Tumors ◽  
Biological Fluids ◽  
Treatment Strategies ◽  
Transcriptional Level ◽  
Special Role ◽  
Primary Brain Tumors ◽  
Mrna Targets ◽  
Development Of Resistance ◽  
Poor Outcomes

Brain tumors in children and adults are challenging tumors to treat. Malignant primary brain tumors (MPBTs) such as glioblastoma have very poor outcomes, emphasizing the need to better understand their pathogenesis. Developing novel strategies to slow down or even stop the growth of brain tumors remains one of the major clinical challenges. Modern treatment strategies for MPBTs are based on open surgery, chemotherapy, and radiation therapy. However, none of these treatments, alone or in combination, are considered effective in controlling tumor progression. MicroRNAs (miRNAs) are 18–22 nucleotide long endogenous non-coding RNAs that regulate gene expression at the post-transcriptional level by interacting with 3′-untranslated regions (3′-UTR) of mRNA-targets. It has been proven that miRNAs play a significant role in various biological processes, including the cell cycle, apoptosis, proliferation, differentiation, etc. Over the last decade, there has been an emergence of a large number of studies devoted to the role of miRNAs in the oncogenesis of brain tumors and the development of resistance to radio- and chemotherapy. Wherein, among the variety of molecules secreted by tumor cells into the external environment, extracellular vesicles (EVs) (exosomes and microvesicles) play a special role. Various elements were found in the EVs, including miRNAs, which can be transported as part of these EVs both between neighboring cells and between remotely located cells of different tissues using biological fluids. Some of these miRNAs in EVs can contribute to the development of resistance to radio- and chemotherapy in MPBTs, including multidrug resistance (MDR). This comprehensive review examines the role of miRNAs in the resistance of MPBTs (e.g., high-grade meningiomas, medulloblastoma (MB), pituitary adenomas (PAs) with aggressive behavior, and glioblastoma) to chemoradiotherapy and pharmacological treatment. It is believed that miRNAs are future therapeutic targets in MPBTs and such the role of miRNAs needs to be critically evaluated to focus on solving the problems of resistance to therapy this kind of human tumors.

Sign in / Sign up

Export Citation Format

Share Document